Background
A 4-year-old child with a respiratory condition was prescribed montelukast 5 mg chewable tablets once daily. For children younger than six, the FDA-recommended dose is 4 mg daily. The 5 mg dose is approved for children ages six and older. The prescribed dose exceeded age-based recommendations and could increase the risk of adverse effects.
What we did
HyperCare flagged the dosing error and PharmPix’s clinical team contacted the prescriber to validate. Because it exceeded FDA pediatric recommendations, the medication was not approved as written. The team provided an age-appropriate dosing recommendation.
The impact
- Prevented inappropriate pediatric dosing
- Reduced the risk of dose-related neuropsychiatric adverse effects
- Reinforced age-appropriate prescribing practices
- Protected patient safety before the medication was dispensed
Clinical protection happens at the point decisions are made. PharmPix helps identify potential medication risks and brings clinical protection to the moments that matter.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.
The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.